{
  "id": "human-subjects-research",
  "title": "Human-Subjects Research",
  "lang": "en",
  "source_lang": "en",
  "summary": "Human-subjects research systematically studies living people or their identifiable information and materials under scientific, ethical, and legal safeguards.",
  "category": "health",
  "subcategory": "medicine",
  "type": "concept",
  "aliases": [
    "Research involving human participants",
    "Human participant research",
    "Research involving human subjects"
  ],
  "generated_at": "2026-11-03",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/human-subjects-research/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/human-subjects-research/",
      "json": "https://aiwiki.page/zh/human-subjects-research.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Human-subjects research is systematic investigation involving living people, their behavior, or information and biological materials that can be linked to them. It includes clinical experiments, interviews, surveys, ethnography, educational studies, and many forms of research using medical records, digital traces, or stored specimens. Its boundaries vary across legal systems: an activity may involve people in an ordinary sense without meeting a particular jurisdiction’s regulatory definition of research involving human subjects.\n\nSuch research supplies much of the evidence used in medicine, public health, education, and social policy. It can establish whether an intervention works, describe how people experience illness or institutions, identify causes of disease, or evaluate changes in services. Its distinctive ethical problem is that the production of knowledge may expose particular individuals or communities to burdens for benefits that are uncertain, delayed, or enjoyed chiefly by others.\n\nModern governance combines scientific standards, independent review, voluntary participation, protection of confidential information, and accountability for harms and results. These arrangements developed partly in response to abusive experiments, but they also address ordinary tensions within legitimate research: between scientific control and individual choice, inclusion and protection, open science and privacy, and institutional interests and participants’ welfare."
    },
    {
      "heading": "Scope and boundaries",
      "text": "Human-subjects research is broader than a clinical trial. An investigator may assign an experimental treatment, observe routine clinical care, interview workers about their employment, study classroom interactions, or analyze identifiable health records without contacting the people described. The defining questions concern the purpose of the activity, the relationship between investigators and participants, and the nature and identifiability of the information or materials involved. Physical intervention is only one possible basis for inclusion.\n\nUnder the United States Common Rule, research is generally a systematic investigation designed to develop or contribute to generalizable knowledge. A human subject is a living individual about whom an investigator obtains information or biospecimens through intervention or interaction and uses, studies, or analyzes them, or obtains, uses, studies, analyzes, or generates identifiable private information or identifiable biospecimens. These are regulatory definitions, not universal philosophical definitions. Studies governed by United States Food and Drug Administration regulations are subject to a partly different framework, and other countries define coverage differently.\n\nThe distinction between research and practice often turns on purpose rather than technique. A hospital may examine its medication errors to improve a local service, while a planned comparison across hospitals may be designed to produce broader knowledge. Both activities can use systematic data collection. An intention to publish does not by itself determine whether an activity is research, and calling a project “quality improvement” does not settle the question. Some projects combine service improvement and research, requiring assessment of their separate components.\n\nPublic health surveillance illustrates another important boundary. Surveillance conducted under public health authority may be legally distinguished from research because its primary purpose is identifying, monitoring, or responding to health threats. A subsequent investigation using surveillance data to answer a separate scientific question may require a different assessment. Similarly, oral history, journalism, and biography may fall outside particular research regulations while remaining subject to professional ethics, privacy law, and duties toward interviewees.\n\nWhether information is identifiable depends on context. Names are direct identifiers, but location histories, rare diagnoses, family relationships, or combinations of demographic attributes may also permit identification. Coded data are not necessarily anonymous: a separate key may preserve a link to individuals. Conversely, some secondary analyses of data that investigators cannot readily link to individuals fall outside specific human-subjects regulations. Regulatory exclusion does not establish that an activity poses no ethical risk, particularly where findings could stigmatize a community or expose a small population indirectly."
    },
    {
      "heading": "Historical development and ethical foundations",
      "text": "Research with people predates modern regulation, encompassing medical observation, physiological experimentation, and social investigation. During the nineteenth and twentieth centuries, laboratory methods, hospitals, military institutions, and government research programs greatly expanded its scale. Scientific ambitions often developed faster than protections for participants. People in prisons, psychiatric institutions, colonial settings, and economically disadvantaged communities were especially exposed to investigations conducted under unequal relationships of authority.\n\nThe Nuremberg Code emerged in 1947 from the judgment in the Doctors’ Trial following World War II. Its ten principles emphasized voluntary consent, scientifically justified experiments, avoidance of unnecessary suffering, proportionality between risk and humanitarian importance, and the participant’s freedom to end participation. The Code responded to crimes committed by Nazi physicians; it was not itself a comprehensive international regulatory system. Its insistence that scientific objectives do not override individual protection nevertheless became a central reference point.\n\nThe World Medical Association adopted the Declaration of Helsinki in 1964 and subsequently revised it, including in 2024. The declaration addresses medical research involving human participants, including research using identifiable human material or data. It connects scientific validity with ethical acceptability, requires independent review, and addresses consent, vulnerability, research registration, publication, and arrangements after trials. Its influence extends through professional standards, journal policies, ethics review, and national rules, although the declaration is not a treaty that automatically has legal force in every jurisdiction.\n\nIn the United States, the United States Public Health Service study of untreated syphilis at Tuskegee became a defining example of abuse. Conducted from 1932 to 1972 among Black men in Alabama, the study involved deception and failure to provide appropriate treatment as effective therapy became available. Public disclosure in 1972 helped prompt the National Research Act of 1974 and the creation of a national commission. The commission’s Belmont Report, published in 1979, identified respect for persons, beneficence, and justice as basic ethical principles.\n\nThese principles address distinct obligations. Respect for persons supports voluntary, informed decisions and additional protection where autonomy is limited. Beneficence requires minimizing harms and assessing potential benefits. Justice concerns the distribution of research burdens and advantages, including who is recruited and who can benefit from results. Contemporary ethics also emphasizes social value, scientific validity, community engagement, and the avoidance of exploitation. These considerations are related but not interchangeable: consent cannot make a scientifically worthless experiment ethical, and a socially valuable objective does not justify exposing individuals to unlimited risk."
    },
    {
      "heading": "Scientific design and the production of reliable knowledge",
      "text": "Scientific validity is an ethical requirement because participants may accept inconvenience, discomfort, or danger in the expectation that a study can produce useful knowledge. A poorly formulated question, an unsuitable comparison, or an analysis incapable of answering the question can make those burdens unjustifiable. Review therefore concerns not only participant information sheets but also the research question, recruitment strategy, measurements, statistical plan, and feasibility of completing the study.\n\nExperimental designs assign interventions, whereas observational designs study exposures and outcomes without investigator assignment. A randomized controlled trial uses chance allocation to reduce systematic differences between comparison groups. Allocation concealment prevents foreknowledge of upcoming assignments, while blinding reduces biases that may arise when participants, clinicians, or assessors know which intervention was received. These techniques address different sources of bias and do not eliminate problems caused by missing outcomes, selective reporting, or poorly chosen measures.\n\nObservational methods serve questions that experiments cannot always answer. A cohort study can follow exposure groups over time, while a case–control study compares previous exposures among people with and without a specified outcome. Epidemiology uses such approaches to study disease patterns and determinants. Their interpretation requires attention to confounding, selection bias, measurement error, and the distinction between association and causation. Ethical acceptability does not imply that a design can support every causal claim made from its results.\n\nQualitative research uses interviews, observation, documents, and other materials to investigate experience, meaning, and social processes. Its quality is not ordinarily assessed through statistical power alone. Sampling may seek depth, diversity of experience, or theoretically informative cases rather than population representativeness. Ethical issues can evolve during fieldwork as relationships develop or sensitive information emerges. A rigid requirement to predict every interview question in advance can conflict with legitimate methodological flexibility, making proportionate oversight important.\n\nIn quantitative studies, sample-size planning links the research question to expected effect size, variability, error rates, and statistical power. Too few participants may yield an inconclusive result; unnecessarily many may expose additional people to burdens without sufficient justification. Outcomes also matter. A change in a biomarker may not establish improvement in survival, function, or quality of life. Use of a surrogate endpoint therefore requires evidence and careful interpretation. Protocols, prespecified analyses, and appropriate handling of deviations help prevent favorable results from being selected after the data are known."
    },
    {
      "heading": "Independent review and regulatory oversight",
      "text": "Independent ethical review separates decisions about participant protection from investigators’ direct interest in completing a study. Review bodies are commonly called research ethics committees or institutional review boards. They assess whether a project is scientifically and ethically acceptable before relevant research activities begin. Their authority may include requiring modifications, approving a protocol, rejecting it, or suspending previously approved work. Institutional permission, funding approval, and regulatory authorization may also be required; none necessarily substitutes for the others.\n\nIn the United States, the Common Rule is a shared federal framework codified by participating departments and agencies. A major revision issued in 2017 generally became applicable in 2019. It governs covered research rather than every investigation involving people in the country. Food and Drug Administration rules separately apply to relevant clinical investigations of regulated products. Additional federal protections address certain research involving pregnant women, fetuses, neonates, prisoners, and children, although the applicability of particular provisions depends on the governing rules and agency.\n\nReview commonly examines risks, anticipated benefits, participant selection, consent, privacy, confidentiality, monitoring, and safeguards against coercion or undue influence. A committee should include relevant scientific expertise and perspectives not confined to the investigators’ professional circle. Members with conflicts of interest ordinarily do not participate in the corresponding approval decision. Independence is therefore both structural and procedural: a committee must be able to question a prestigious investigator or commercially important project without its decision being controlled by those interests.\n\nNot all projects require the same level of review. Some jurisdictions recognize exempt categories or expedited procedures for specified kinds of low-risk research. “Exempt” generally means exempt from particular regulatory requirements, not exempt from all ethical obligations or other law. Likewise, expedited review usually describes a procedure performed by designated reviewers rather than a guarantee of rapid approval. Under the revised Common Rule, routine continuing review is not required for some categories of research, but obligations concerning amendments, relevant incidents, and institutional oversight can remain.\n\nInternational arrangements differ. European Union medicinal-product trials operate within a framework that includes Regulation (EU) No 536/2014, alongside applicable ethical and data-protection requirements. Other studies may be governed by national or regional laws and institutional systems. Multicenter research can use coordinated or single-review arrangements to reduce duplication, but local knowledge remains important for language, recruitment, care pathways, and cultural context. Approval in one country does not automatically authorize work elsewhere, and an ethics committee cannot make an otherwise unlawful study lawful."
    },
    {
      "heading": "Consent, understanding, and voluntary participation",
      "text": "Informed consent is a continuing process through which a person receives relevant information, understands its implications, and voluntarily decides whether to participate. A signed document records part of that process but does not establish that understanding or voluntariness actually occurred. Material information ordinarily includes the study’s purpose, procedures, duration, foreseeable risks and burdens, potential benefits, alternatives, confidentiality arrangements, compensation or costs, and whom to contact about questions or injuries.\n\nCommunication must distinguish research from individualized treatment. Investigators follow a protocol designed to answer a question, and choices may be constrained by randomization, eligibility rules, or standardized procedures. The belief that every research decision is made solely for the participant’s personal clinical benefit is often called therapeutic misconception. It is particularly relevant when a treating clinician is also an investigator or when an early-phase study primarily evaluates safety, tolerability, or dose rather than therapeutic effectiveness.\n\nUnderstanding depends on presentation as well as disclosure. Technical language, excessive document length, limited health literacy, and unfamiliar probabilities can obstruct meaningful decisions. Translation alone may not resolve conceptual differences or reading difficulties. Interactive explanation and methods that ask participants to describe key information in their own words can reveal misunderstandings. Electronic consent can support audiovisual explanation and remote participation, but it also creates questions about identity verification, accessibility, opportunities for questions, and whether the person controls the device being used.\n\nVoluntariness can be compromised by threats, dependency, or offers that distort a person’s assessment of burdens. Coercion involves pressure through a threat of harm or penalty; undue influence concerns an inappropriate inducement or other influence that undermines voluntary choice. Payment is not inherently coercive. Reimbursement for travel, compensation for time, and incentives require contextual assessment, including their amount, timing, and relation to participants’ circumstances. The right to withdraw should be explained together with practical limits, such as the inability to remove information already incorporated into an aggregate analysis.\n\nConsent can sometimes be waived or altered under legally specified conditions and independent review. For example, the Common Rule permits certain waivers where research presents no more than minimal risk, cannot practicably be conducted without the waiver, and satisfies additional protections for participants’ rights and welfare. Emergency research has separate, narrowly defined pathways in some systems. Waiver of a signature is different from waiver of consent itself. Deception in behavioral research may also require specific justification and, where appropriate, debriefing; investigator preference or difficulty recruiting participants is not sufficient justification on its own."
    },
    {
      "heading": "Risk, potential benefit, and safety monitoring",
      "text": "Research risks include more than bodily injury. A blood draw can cause pain or bruising; an experimental medicine may produce serious toxicity; an interview can evoke distress; disclosure of sensitive information can affect employment, insurance, relationships, or legal exposure. Research can also create social or economic harms for groups, even when individuals are not named. Risk assessment therefore considers the probability, magnitude, duration, reversibility, and distribution of possible harms, rather than treating all burdens as equivalent.\n\nPotential benefits must be separated into direct benefits to participants and benefits to knowledge or society. A research-only scan, extra biopsy, or blood sample may contribute information without offering direct clinical benefit. Payment is generally treated as compensation or incentive rather than a medical benefit that offsets procedural risk. Ethical review assesses whether risks have been minimized through sound design and whether the remaining risks are reasonable in relation to anticipated benefits and the importance of the knowledge sought. This is a structured judgment, not a simple arithmetic calculation.\n\n“Minimal risk” is a regulatory threshold, not a synonym for no risk. Under the Common Rule, it refers to harms or discomforts not greater in probability and magnitude than those ordinarily encountered in daily life or during routine physical or psychological examinations or tests. Applying this benchmark can be difficult, especially for sensitive data or populations whose daily circumstances are unusually hazardous. Additional rules may impose different risk limits for research involving children or other protected groups.\n\nIn intervention studies, monitoring continues after enrollment. An adverse event is an unfavorable medical occurrence during participation and does not necessarily mean the intervention caused it. Seriousness, severity, expectedness, and causal relatedness are separate concepts. Investigators and sponsors assess events, communicate relevant findings, and meet applicable reporting requirements. A data and safety monitoring board may independently examine accumulating results, including confidential comparative data, and advise whether a study should continue, change, or stop for harm, convincing benefit, or futility.\n\nUse of a placebo or no-treatment control requires particular scrutiny when an effective intervention exists. Clinical equipoise describes genuine uncertainty within the relevant expert community about the comparative therapeutic merits of trial interventions. The permissibility of placebo depends on factors including available treatment, scientific necessity, the consequences of withholding therapy, and the governing ethical framework. Safety provisions may include rescue treatment, withdrawal criteria, emergency unblinding, and referral arrangements. They also include clear plans for research-related injury, whose compensation and treatment requirements vary by jurisdiction."
    },
    {
      "heading": "Fair selection, vulnerability, and community relationships",
      "text": "Justice in participant selection concerns both excessive exposure to risk and unjustified exclusion from research benefits. Historically, researchers often recruited people who were readily controlled or economically dependent while the resulting knowledge principally served more advantaged groups. Fair selection requires a scientific and ethical explanation for the population studied. Convenience, low cost, or weak bargaining power is not by itself sufficient justification for concentrating burdens on a particular group.\n\nVulnerability is best understood in relation to the research setting rather than as an immutable label. A person may face limited decision-making ability, dependence on an institution, economic insecurity, language barriers, or a threat of stigma. These conditions call for safeguards addressing the actual source of risk. Treating every member of a broad category as incapable can be paternalistic and can exclude populations whose health needs require investigation. Conversely, formal legal competence does not eliminate pressures created by a dependent relationship.\n\nChildren generally require parental or guardian permission and, when capable, their own affirmative agreement, commonly called assent. Failure to object is not equivalent to assent. Applicable rules distinguish research offering a prospect of direct benefit from research that does not, and may impose different risk limits. Adults whose decision-making capacity is impaired may require an authorized representative, attention to their preferences and dissent, and reassessment when capacity changes. A diagnosis such as dementia does not by itself establish incapacity for every research decision.\n\nOther settings create distinctive concerns. Prisoners may experience restricted choices and institutional pressures; employees and students may fear consequences for refusing a supervisor or teacher. Research during pregnancy must address risks to the pregnant participant and fetus without assuming that exclusion is always protective. Persistent exclusion can leave clinicians with weak evidence about interventions subsequently used in the excluded population. Questions of health equity therefore concern representation and access to potential benefits as well as protection from harm.\n\nCommunity engagement can improve the relevance of research questions, recruitment materials, outcome selection, and interpretation. In research involving Indigenous peoples, community governance, collective interests, and control over data may be central, alongside individual consent. Consultation is not interchangeable with permission from an authorized body, and neither automatically replaces each participant’s decision. Community representatives may also hold differing views. Engagement requires clarity about whose perspectives are represented, what decisions can be influenced, and what commitments investigators can realistically fulfill."
    },
    {
      "heading": "Privacy, biological materials, and digital environments",
      "text": "Privacy concerns access to people and their personal circumstances; confidentiality concerns how entrusted information is handled and disclosed. Data privacy becomes especially important when research combines medical, genetic, behavioral, and location information. A study can respect consent at enrollment yet create substantial risks through insecure storage, excessive collection, or later uses outside participants’ reasonable expectations. Protection therefore extends across collection, transfer, analysis, retention, and destruction or long-term archiving.\n\nTechnical safeguards include role-based access, encryption, separation of identifying information from research records, audit trails, and controlled environments for sensitive analysis. Organizational measures include staff training, access agreements, incident response, and restrictions on onward sharing. Removing names is only one step. Rich datasets can permit reidentification through linkage with external sources, and genomic data may reveal information about biological relatives as well as the person sampled. Claims that a dataset is “anonymous” require attention to realistic identification possibilities and the applicable legal definition.\n\nStored specimens and data raise questions about future research that cannot be fully specified at initial collection. Biobanks may retain blood, tissue, DNA, and associated records for many years. Consent models range from permission for a particular project to broader permission for defined categories of future use. Broad consent is not unlimited authorization: governance, access review, restrictions on use, and communication of material changes remain important. Under the Common Rule, “broad consent” also has a specific regulatory meaning distinct from the phrase’s general ethical use.\n\nDigital research can involve wearable sensors, smartphone applications, online platforms, and electronic health records. The apparent public availability of a post does not automatically resolve ethical questions about its collection or quotation. A searchable verbatim quotation may identify an author even after a username is removed. Passive monitoring can capture bystanders who never enrolled, while location or interaction data can reveal intimate relationships. Studies using machine learning also require attention to how training datasets were obtained, whether reuse is authorized, and whether model outputs could expose sensitive information.\n\nReturning individual findings requires separate planning. A research result may lack the validation or clinical context necessary for diagnosis, even when it appears medically important. Protocols may distinguish primary findings, incidental findings, and aggregate study results, and consider analytic reliability, clinical significance, actionability, participant preferences, and available support. Data-protection requirements, including those under the European Union’s General Data Protection Regulation, may apply alongside research regulation. Ethical consent to participate and a legal basis for processing personal data are related but distinct requirements."
    },
    {
      "heading": "Transparency, international collaboration, and continuing accountability",
      "text": "Research obligations continue beyond data collection. Concealing unfavorable results, selectively publishing outcomes, or abandoning dissemination can waste participants’ contributions and distort the evidence available for care and policy. Prospective trial registration creates a public record of a planned investigation and makes later changes more visible. The World Health Organization’s registration framework and journal policies have helped establish registration as a standard expectation for clinical trials, while specific legal reporting duties depend on the trial and jurisdiction.\n\nA registry entry, a published protocol, and a journal article perform different functions. Registration identifies a study and its principal planned features; a protocol specifies methods and governance; results reporting describes what actually occurred and what was found. Reporting guidance such as the CONSORT statement promotes fuller reporting of randomized trials but cannot itself guarantee ethical conduct or eliminate bias. Appropriate reporting includes adverse outcomes, departures from the plan, limitations, and enough methodological detail to permit critical assessment.\n\nFinancial and professional interests can influence study design, recruitment, interpretation, and publication. Investigators may receive industry payments, hold patents, or benefit academically from positive findings. Institutions may also have financial interests. Disclosure makes these relationships visible but does not automatically resolve them. Management can involve independent analysis, limits on recruitment roles, contractual protection of publication rights, or removal of particular responsibilities. Accountability also depends on reliable records, mechanisms for reporting concerns, and investigation of fabrication, falsification, and other serious misconduct.\n\nInternational collaborations introduce differences in resources, disease burden, law, and access to care. A study conducted in a lower-resource setting may be scientifically necessary and locally valuable, but ethical assessment must examine whether its questions respond to local priorities and whether burdens and benefits are fairly distributed. The 2016 international ethical guidelines issued by the Council for International Organizations of Medical Sciences address research in varied resource settings. Local ethical review, meaningful partnerships, and arrangements concerning access to beneficial interventions help distinguish collaboration from exploitation.\n\nPublic health emergencies intensify these issues rather than removing them. During outbreaks of infectious disease, rapid studies may be essential for evaluating treatments or vaccines, yet urgency can complicate consent, laboratory capacity, monitoring, and coordination. Adaptive methods and shared protocols can accelerate learning without abandoning independent review. Practical accountability includes communicating results to participating communities, explaining material changes during a study, honoring commitments about specimens and data, and specifying responsibilities for post-trial care or access before enrollment begins."
    }
  ],
  "links": [
    "medicine",
    "public-health",
    "education",
    "clinical-trial",
    "public-health-surveillance",
    "world-war-ii",
    "declaration-of-helsinki",
    "syphilis",
    "belmont-report",
    "ethics",
    "randomized-controlled-trial",
    "allocation-concealment",
    "blinding-clinical-trials",
    "cohort-study",
    "case-control-study",
    "epidemiology",
    "causation",
    "biomarker",
    "quality-of-life",
    "surrogate-endpoint",
    "institutional-review-board",
    "common-rule",
    "informed-consent",
    "health-literacy",
    "biopsy",
    "placebo",
    "decision-making-capacity",
    "dementia",
    "pregnancy",
    "health-equity",
    "data-privacy",
    "dna",
    "machine-learning",
    "diagnosis",
    "consort-statement",
    "infectious-disease",
    "vaccine"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}